MediWound’s NexoBrid Shows Significant Beneficial Impact On Pediatric Burn Patients
MediWound Ltd (NASDAQ:MDWD) has announced topline results from Phase 3 pediatric study with NexoBrid to treat severe thermal burns. The 145-subject…
MediWound Reports Primary Endpoints In Phase 3 Pediatric Study Trial Of NexoBrid For Eschar Removal Of Severe Thermal Burns
Primary Endpoints Met with Highly Statistically Significant Results Compared with Standard-of-Care
YAVNE, Israel, July 20, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical
20 Stocks Moving in Thursday’s Pre-Market Session
Gainers
Alterity Therapeutics Ltd (NASDAQ: ATHE) shares rose 64% to $2.14 in pre-market trading. Alterity Therapeutics recently said it received EU regulatory guidance for ATH434 Phase 2 clinical trial.
Mid-Afternoon Market Update: US Stocks Mostly Flat; DiaMedica Therapeutics Shares Plunge
Toward the end of trading Tuesday, the Dow traded up 0.04% to 34,295.41 while the NASDAQ rose 0.13% to 14,518.98. The S&P traded flat at 4,290.65.
Why Shares Of MediWound And Vericel Fell On Tuesday
Shares of MediWound (NASDAQ: MDWD) and its development partner, Vericel Corporation (NASDAQ: VCEL), are trading lower after MediWound received a Complete Response Letter from the FDA for its NexoBrid Biologics License Application.
Mid-Day Market Update: Gold Drops Over 1%; Cerevel Therapeutics Shares Spike Higher
Midway through trading Tuesday, the Dow traded up 0.37% to 34,411.60 while the NASDAQ fell 0.03% to 14,495.75. The S&P also rose, gaining 0.16% to 4,297.63.
Mid-Morning Market Update: Markets Mostly Higher; FactSet Research Reports Mixed Q3 Results
Following the market opening Tuesday, the Dow traded up 0.40% to 34,420.32 while the NASDAQ fell 0.10% to 14,486.23. The S&P also rose, gaining 0.14% to 4,296.59.
FDA Strikes Off MediWound – Vericel’s NexoBrid Biologics License Application; Stocks Drop
Vericel Corporation’s (NASDAQ:VCEL) development partner, MediWound Ltd (NASDAQ:MDWD), received a complete response letter from FDA regarding the NexoBrid application seeking approval for eschar…